Annexon Bioscience Inc
BioTech/Drugs - South San Francisco, CA, US
Annexon Bioscience Inc Employees
Annexon Bioscience Inc Senior Management
Annexon Bioscience Inc Details
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company's pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.
Annexon Bioscience Inc Technologies
Email Providers
Outlook
CMS
WP Engine
Web Performance Monitoring
New Relic
Other
Microsoft Office 365
Hosting
Google Cloud Hosting
CSS and JavaScript Libraries
Bootstrap Framework